ArticleCancer research communications2023

Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy.

Mengwu Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.